<DOC>
	<DOCNO>NCT00211913</DOCNO>
	<brief_summary>S. aureus common pathogen encountered infection associate cardiovascular surgery . StaphVAXÂ® bivalent S. aureus type 5 8 vaccine contains purify capsular polysaccharide ( CPS ) implicate major factor invasiveness S. aureus . Immunoprophylaxis vaccinate S. aureus prior surgery could provide sufficient antibody concentration surgery wound heal period decrease risk S. aureus infection . This study aim demonstrate immunogenicity safety single dose StaphVAX patient candidate cardiovascular surgery .</brief_summary>
	<brief_title>StaphVAX Cardiovascular Surgery Patients</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<criteria>Candidate cardiovascular surgery Expected comply protocol Negative pregnancy test appropriate Written inform consent Known S. aureus infection past 3 month Known infection past 2 week Known HIV infection Pregnancy breastfeed Immunomodulatory drug Malignancy treatment malignancy within past six month , basal cell , localize squamous cell carcinoma skin , carcinoma situ cervix , early stage prostate cancer investigational drug , vaccine product past 30 day Hypersensitivity component StaphVAX</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>